Last reviewed · How we verify

NCT03095391

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™

Completed Last updated 26 December 2018
What this trial tests

trial testing VFI in Kidney Diseases in 32 participants. Completed in 20 September 2017.

Timeline
13 June 2017
Primary endpoint
20 September 2017
20 September 2017

Quick facts

Lead sponsorFAST BioMedical
StatusCompleted
Study typeOBSERVATIONAL
Enrollment32
Start date13 June 2017
Primary completion20 September 2017
Estimated completion20 September 2017
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

FAST BioMedical

Who can join

Adults 18 to 75, any sex, with Kidney Diseases or Renal Insufficiency, Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 2b, prospective, open-label study designed to evaluate the safety, tolerability, PK, and PD of FAST PV and mGFR Technology in healthy subjects and patients with varying degrees of renal impairment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. A Novel Method for Rapid Bedside Measurement of GFR.
    Rizk DV, Meier D, Sandoval RM, Chacana T, et al · · 2018 · cited 45× · PMID 29748326 · DOI 10.1681/asn.2018020160
  2. A Novel Fluorescent Clinical Method to Rapidly Quantify Plasma Volume.
    Molitoris BA, George AG, Murray PT, Meier D, et al · · 2019 · cited 5× · PMID 30844821 · DOI 10.1159/000496480

Verify or expand the search:

Other trials of VFI

Trials testing the same drug.

Other recruiting trials for Kidney Diseases

Currently open trials in the same condition.

Other FAST BioMedical trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03095391.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing